Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon

Background. Current treatment of chronic hepatitis C with pegylated interferon and ribavirin has the ability to eliminate viral infection in about half of the patients treated. Therapeutic options, for those with remaining chronic hepatitis, will remain limited until novel antivirals become availabl...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Meyer, Douglas F., Tobias, Hillel, Min, Albert D., Rajendra, Arathi, Zic, Ivanka, Brettholz, Edward, Clain, David J., Klion, Franklin, Bernstein, David, Bodenheimer, Henry C.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Hindawi Publishing Corporation 2010
Gaiak:
Clinical Study
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3003973/
https://ncbi.nlm.nih.gov/pubmed/21188197
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2010/537827
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak